No connection

Search Results

ARQT vs TXG

ARQT
Arcutis Biotherapeutics, Inc.
BEARISH
Price
$22.75
Market Cap
$2.82B
Sector
Healthcare
AI Confidence
85%
TXG
10x Genomics, Inc.
NEUTRAL
Price
$22.97
Market Cap
$2.93B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ARQT
--
TXG
--
Forward P/E
ARQT
17.79
TXG
114.85
P/B Ratio
ARQT
14.81
TXG
3.68
P/S Ratio
ARQT
7.5
TXG
4.56
EV/EBITDA
ARQT
-359.13
TXG
-38.94

Profitability

Gross Margin
ARQT
90.24%
TXG
69.13%
Operating Margin
ARQT
14.2%
TXG
-9.42%
Profit Margin
ARQT
-4.29%
TXG
-6.77%
ROE
ARQT
-9.3%
TXG
-5.78%
ROA
ARQT
-1.96%
TXG
-6.4%

Growth

Revenue Growth
ARQT
81.5%
TXG
0.6%
Earnings Growth
ARQT
--
TXG
--

Financial Health

Debt/Equity
ARQT
0.6
TXG
0.11
Current Ratio
ARQT
3.17
TXG
4.46
Quick Ratio
ARQT
2.83
TXG
3.95

Dividends

Dividend Yield
ARQT
--
TXG
--
Payout Ratio
ARQT
0.0%
TXG
0.0%

AI Verdict

ARQT BEARISH

ARQT's Piotroski F-Score of 1/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and no dividend, signaling poor operational health. Despite strong revenue growth of 81.5% YoY and a forward P/E of 17.79, the company remains unprofitable with a negative profit margin of -4.29% and no intrinsic value or Graham Number available. Insider selling totaling $5.12M in the last six months, including significant sales by the CEO and directors, reinforces bearish sentiment. The stock trades at a premium to its fundamentals, with a Price/Sales of 7.50 and Price/Book of 14.81, suggesting overvaluation relative to earnings and book value. Analysts' strong_buy consensus appears disconnected from the underlying financial deterioration.

Strengths
81.5% YoY revenue growth indicates strong market expansion and product demand
High gross margin of 90.24% reflects efficient production and pricing power
Strong current and quick ratios (3.17 and 2.83) suggest solid short-term liquidity
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and operational instability
Negative ROE (-9.30%) and ROA (-1.96%) indicate poor capital efficiency and unprofitability
Insider selling of $5.12M in 6 months, including CEO and directors, raises governance concerns
TXG NEUTRAL

TXG exhibits a stark divergence between its strong balance sheet liquidity and its poor operational health, evidenced by a weak Piotroski F-Score of 2/9. While the company maintains a very low Debt/Equity ratio (0.11) and a robust Current Ratio (4.46), revenue growth has stagnated at 0.60% YoY. The stock is currently trading at a significant premium with a Forward P/E of 114.85, despite negative profit margins. Recent price recovery is strong, but insider selling and bearish technical trends suggest caution.

Strengths
Exceptional liquidity with a Current Ratio of 4.46
Very low leverage (Debt/Equity of 0.11)
Strong Gross Margins at 69.13%
Risks
Stagnant revenue growth (0.60% YoY)
Poor financial trend indicated by Piotroski F-Score of 2/9
Extremely high valuation (Forward P/E 114.85)

Compare Another Pair

ARQT vs TXG: Head-to-Head Comparison

This page compares Arcutis Biotherapeutics, Inc. (ARQT) and 10x Genomics, Inc. (TXG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile